Drug Switch Leads to Superior HbA1c Reduction in Sitagliptin vs. Victoza Study
Switching from sitagliptin to Victoza (liraglutide [rDNA origin]; Novo Nordisk), in combination with metformin, showed superior HbA1c reductions vs. continuing with sitagliptin in adults with type 2 diabetes. Findings from the LIRA-SWITCH trial were presented at ENDO 2016.
LIRA-SWITCH was a 26-week, randomized, double-blind, double-dummy, active-controlled trial (n=407) that evaluated the efficacy and safety of Victoza as an add-on to metformin in adults with type 2 diabetes who switched from sitagliptin. At Week 26, patients who switched to Victoza (n=203) achieved a superior HbA1c reduction vs. those who continued their sitagliptin (–1.14% vs. –0.54%, 95% CI: –0.82 to –0.40; P<0.0001).
Also, patients who switched to Victoza had a significantly greater body weight reductions vs. those who continued their sitagliptin (–3.31kg vs. –1.64kg, 95% CI: –2.34 to –0.99; P<0.0001).
More adults achieved HbA1c targets <7% when treated with Victoza vs. sitagliptin (50.6% vs. 26.9%; P<0.0001) and ≤6.5% (29.5% vs. 9.9%; P<0.0001). In addition, patients treated with Victoza showed significantly greater reductions in fasting plasma glucose vs. sitagliptin (–33.09mg/dL vs. –13.19mg/dL; P<0.0001).
There were no reports of severe hypoglycemia or nocturnal hypoglycemia in either treatment arm, researchers noted.
Victoza, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated as adjunct to diet and exercise, to improve glycemic control in type 2 diabetes.
For more information visit Endocrine.org.